458,751 Shares in Omnicell, Inc. $OMCL Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH bought a new position in Omnicell, Inc. (NASDAQ:OMCL) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 458,751 shares of the company’s stock, valued at approximately $15,620,000.

Other hedge funds also recently made changes to their positions in the company. Nykredit A S acquired a new stake in shares of Omnicell during the 2nd quarter valued at approximately $26,000. Versant Capital Management Inc lifted its stake in Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Omnicell during the second quarter worth $105,000. State of Wyoming acquired a new position in Omnicell in the second quarter worth $110,000. Finally, Central Pacific Bank Trust Division acquired a new position in Omnicell in the third quarter worth $107,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Up 1.6%

NASDAQ:OMCL opened at $35.95 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average of $34.59 and a 200-day moving average of $38.50. The firm has a market capitalization of $1.63 billion, a PE ratio of 42.80, a price-to-earnings-growth ratio of 0.89 and a beta of 0.98. Omnicell, Inc. has a 52 week low of $29.09 and a 52 week high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. The business had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same quarter last year, the business posted $0.45 EPS. The business’s revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts predict that Omnicell, Inc. will post 1.41 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on OMCL shares. Wells Fargo & Company lowered their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Piper Sandler restated an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Finally, Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

About Omnicell

Omnicell, Inc provides medication-management technology and related services for health care providers. Its solutions are designed to help hospitals, health systems, retail pharmacies and other care settings manage medication inventory, improve workflow efficiency and support medication adherence.

The company’s offerings include automated medication dispensing systems, central pharmacy automation, medication packaging and adherence solutions, pharmacy inventory management tools, and software for medication-use analytics and workflow management.